RCS - ReNeuron Group plc - ReNeuron to present at ISCT 2022 in San Francisco

ReNeuronAnnouncement

03/05/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220503:nRSC9376Ja&default-theme=true

RNS Number : 9376J  ReNeuron Group plc  03 May 2022

 
ReNeuron Group plc

("ReNeuron" or the "Company")

 

ReNeuron to present at International Society of Cell and Gene Therapy

Dr Randolph Corteling, Vice President of Research invited as guest speaker

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes
Technologies, announces that the Company will be attending the International
Society of Cell and Gene Therapy Annual Meeting (ISCT 2022) from the 4-7 May
in San Francisco, California. As part of the event, Dr Corteling will be
presenting as an exosomes global subject matter expert in two separate
sessions:

 

·    State of the Art in Exosomes (EV) Research: Rigor and Function on
Thursday 5 May: 08:45 PDT

·    Neural Stem cell Derived EVs as Novel therapeutic agents on Saturday
7 May: 07:35 PDT

 

ISCT 2022 brings together a network of leading clinicians, regulators,
researchers, technologists and industry partners that aim to translate cell
and gene therapies into safe and effective therapies to improve patients'
lives worldwide. ISCT 2022 will draw from international experts across
industry, academic and regulatory spheres with the purpose of building
consensus to drive the field forward through a series of abstracts,
presentations, roundtables, workshops and networking. Further information on
the event can be found here: https://www.isctglobal.org/isct2022/home
(https://www.isctglobal.org/isct2022/home)

 

Each year, the ISCT dedicates a full day to a Scientific Signature Series
Event to gather key opinion leaders in a chosen field. This year, the chosen
field is Exosomes (also known as Extracellular Vesicles or "EVs") and the
focus will be on how native EVs of human origin and engineered human EVs are
used in clinically relevant animal models or in human trials.

 

CFO, Catherine Isted, will also be presenting a short corporate presentation
as part of the event. This will be the first time the Company has presented
its full range of seven conditionally immortalised stem cell lines from which
ReNeuron can produce exosomes encompassing four areas of the brain, the
retina, liver and pancreas. This highlights how ReNeuron's multiple
conditionally immortalised cell lines allow exosomes to be highly customised
and optimised for partners specific payloads and targeting needs.

 

All Company presentations will be made available after the event on the
Company's website: https://www.reneuron.com/investors/presentations/
(https://www.reneuron.com/investors/presentations/)

 

 

 
ENDS

 

 

Contacts:

 

 ReNeuron                                      www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                           Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Walbrook PR (Media & Investor Relations)      +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus / Alice Woodings                 +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZGZDKLFGZZM